...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease
【24h】

Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease

机译：CX601（Darvadstrocel）用于治疗肛周瘘管克罗恩病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ABSTRACT Introduction: Given the well-documented difficulty to treat perianal fistulizing Crohn's disease (pCD), with 40% of patients experiencing recurrence even after reiterative surgery and advanced medical therapy, research in this field has focused on the role of mesenchymal stem cells (MSC). Areas covered: The aim of this article is to furnish an overview of the pathogenetic mechanisms, clinical applications and evidences for the use of MSC for pCD with particular focus on adipose-derived allogenic MSC including darvadstrocel. Expert Opinion: The effect of MSC on fistula healing is probably mediated by their anti-inflammatory properties more than by their ability to engraft and trans-differentiate in the healthy tissue. A holistic treatment of pCD, addressing different pathophysiological factors, may represent the key for an improvement in the healing rate. In this setting, MSC might play a role as 'augmentation' therapy in combination with more conventional treatments. Whether MSC have benefit in non-complex fistula in biological naive patients, in complex fistula with many tracts and/or in rectovaginal fistulas, are unexplored fields that need further investigation. A central registry of pCD patients undergoing treatment with MSC should be created in order to elucidate the efficacy, safety and costs of stem cells treatment on long term follow up.
机译：摘要介绍：鉴于良好的难以治疗肛周瘘的难题（PCD），甚至在重新审查和先进的医疗治疗后，40％的患者均可复发，这一领域的研究专注于间充质干细胞的作用（MSC ）。所涵盖的领域：本文的目的是提供致病机制，临床应用和使用MSC用于PCD的概述，特别关注脂肪衍生的同种异体MSC，包括Darvadstrocel。专家意见：MSC对瘘管愈合的影响可能由其抗炎特性介导的，而不是通过它们在健康组织中的侵入和反式分化的能力来介导。 PCD的整体处理，解决了不同的病理生理因素，可以代表愈合率改善的关键。在此设置中，MSC可能与更常规治疗组合的“增强”治疗作用。 MSC是否在生物幼稚患者中对非复杂瘘中的益处，在具有许多尸体和/或矫直物瘘的复杂瘘管中，是需要进一步调查的未开发领域。应制定接受MSC治疗的PCD患者的中央注册表，以阐明干细胞治疗长期随访的疗效，安全性和成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号